On the HCPLive multiple sclerosis page, resources on the topics of medical news and expert insight into MS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on primary progress and relapsing-remitting multiple sclerosis, and more.
December 9th 2022
As the treatment paradigm for neurologic diseases rapidly progresses, the need for more thorough biomarker tools to measure disease progression and severity has increased. In recent years, GFAP has emerged as a valuable candidate to add to the existing panel.
FDA Continues Investigation of MS Drug
The US Food and Drug Administration (FDA) is continuing to investigate a potential link between Novartis's multiple sclerosis (MS) drug Gilenya (fingolimod) and a single case of a rare and serious brain infection in a European patient.
Worldwide Prevalence of Multiple Sclerosis Is on the Rise
A worldwide survey conducted by the Multiple Sclerosis International Federation has discovered that 2.3 million people around the globe currently live with multiple sclerosis (MS) - a 10 percent increase in the autoimmune disease's prevalence since 2008.
Turning Research Focus to Gray Matter Sheds Light on Multiple Sclerosis Origin
Though former imaging studies have proposed that white matter dysfunction predicts the development of multiple sclerosis (MS), a recent study supported by the National Institutes of Health (NIH) suggests that those previous researchers were concentrating on the wrong area of the brain.
iPad App Offers Promising New Way to Evaluate and Monitor MS Symptoms
Clinicians can use the MSPT, an iPad-based neurological performance test that simulates and extends the Multiple Sclerosis Functional Composite, to measure motor and visual function in patients with multiple sclerosis.
Gains in Disease-related Disability Seen with Alemtuzumab in Patients with Multiple Sclerosis
Patients with relapsing-remitting multiple sclerosis treated for two years with alemtuzumab demonstrated improved disease-related disability scores compared to patients who received treatment with subcutaneous interferon beta-1a.
Researchers Identify Cardiotoxicity Risk Factor in MS Patients Receiving Mitoxantrone Injections
Though EMD Serono's Novantrone (mitoxantrone) injection is the only drug approved by the US Food and Drug Administration (FDA) for the treatment of secondary progressive multiple sclerosis (SPMS), progressive-relapsing multiple sclerosis (PRMS), or worsening relapsing-remitting multiple sclerosis (RRMS), its use is associated with significant risks.
Clinical Outcome Measures and Future Directions for Multiple Sclerosis Care Centers
June 2nd 2013To prepare for coming changes at the CMS driven by the Affordable care Act, multiple sclerosis care centers should begin to develop MS-specific electronic health record templates that record clinical outcome measures.
A Patient-Centered Medical Home Model for Measuring Multiple Sclerosis Outcomes
June 2nd 2013With so many different interdependent symptoms affecting MS pathogenesis, effective treatment requires intervention by a multidisciplinary team, with progress assessed by validated instruments that measure variables such as physical health, psychological health, and social relationships.